HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-Free Survival in HER2-Positive Early Breast Cancer Treated With Neoadjuvant-Adjuvant Trastuzumab After 2 Years of Treatment-Free Follow-up

Total pathologic complete response (tpCR) was associated with improved event-free survival, adding to evidence that tpCR is associated with clinical benefit in HER2-positive early breast cancer.

 European Journal of Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.